{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:38:26Z","timestamp":1772602706152,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with inflammatory bowel disease (IBD) have an increased risk of venous thromboembolism (VTE). Alongside the traditional acquired and genetic risk factors for VTE, patients with IBD have pathogenic and clinical peculiarities that are responsible for the increased number of thromboembolic events occurring during their life. A relevant role in modifying this risk in a pro or antithrombotic manner is played by pharmacological therapies and surgery. The availability of several biological agents and small-molecule drugs with different mechanisms of action allows us to also tailor the treatment based on the individual prothrombotic risk to reduce the occurrence of VTE. Available review articles did not provide sufficient and updated knowledge on this topic. Therefore, we assessed the role of each single treatment, including surgery, in modifying the risk of VTE in patients with IBD to provide physicians with recommendations to minimize VTE occurrence. We found that the use of steroids, particularly if prolonged, increased VTE risk, whereas the use of infliximab seemed to reduce such risk. The data relating to the hypothesized prothrombotic risk of tofacitinib were insufficient to draw definitive conclusions. Moreover, surgery has an increased prothrombotic risk. Therefore, implementing measures to prevent VTE, not only with pharmacological prophylaxis but also by reducing patient- and surgery-specific risk factors, is necessary. Our findings confirm the importance of the knowledge of the effect of each single drug or surgery on the overall VTE risk in patients with IBD, even if further data, particularly regarding newer drugs, are needed.<\/jats:p>","DOI":"10.3390\/jcm9072115","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T09:49:11Z","timestamp":1594028951000},"page":"2115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-7298","authenticated-orcid":false,"given":"Alfredo","family":"Papa","sequence":"first","affiliation":[{"name":"Internal Medicine and Gastroenterology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy"},{"name":"Universit\u00e0 Cattolica del S. Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tursi","sequence":"additional","affiliation":[{"name":"Servizio di Gastroenterologia Territoriale ASL BAT, Barletta-Andria-Trani, 76123 Barletta, Andria, Trani, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center, IRCCS Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianludovico","family":"Rapaccini","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy"},{"name":"Universit\u00e0 Cattolica del S. Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Internal Medicine and Gastroenterology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy"},{"name":"Universit\u00e0 Cattolica del S. Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Papa","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del S. Cuore, 00168 Roma, Italy"},{"name":"Digestive Surgery Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ajg.2011.53","article-title":"Venous thromboembolism in Inflammatory Bowel Disease: An Epidemiological Review","volume":"106","author":"Murthy","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000116773","article-title":"Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects","volume":"26","author":"Papa","year":"2008","journal-title":"Dig. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1572-0241.2003.04026.x","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"99","author":"Solem","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies","volume":"8","author":"Fumery","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.12294","article-title":"Meta-analysis: The risk of venous thromboembolism in patients with inflammatory bowel disease","volume":"37","author":"Yuhara","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-0037-1615600","article-title":"The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population- based cohort study","volume":"85","author":"Bernstein","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/gut.2010.228585","article-title":"Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: A population-based nationwide study","volume":"60","author":"Kappelmann","year":"2011","journal-title":"Gut"},{"key":"ref_8","first-page":"485","article-title":"Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease","volume":"56","author":"Nylund","year":"2013","journal-title":"JPGN"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1572-0241.2003.07491.x","article-title":"Review article: Inherited thrombophilia in inflammatory bowel disease","volume":"98","author":"Papa","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1572-0241.2006.00943.x","article-title":"Inflammation and coagulation in inflammatory bowel disease: The clot thickens","volume":"102","author":"Danese","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MEG.0b013e3282faa769","article-title":"PAI-1 and TAFI in inflammatory bowel disease: The yin and yang of the fibrinolytic system","volume":"20","author":"Danese","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1055\/s-0035-1556590","article-title":"Hypercoagulability and Platelet Abnormalities in Inflammatory Bowel Disease","volume":"41","author":"Senchenkova","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2036.2000.00824.x","article-title":"Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease","volume":"14","author":"Carty","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0049-3848(86)90031-9","article-title":"The influence of glutathione and other thiols on human platelet aggregation","volume":"44","author":"Thomas","year":"1986","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00054725-200407000-00007","article-title":"Rampton. Formation of Platelet-Leukocyte Aggregates in Inflammatory Bowel Disease","volume":"10","author":"Peter","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.13265","article-title":"The influence of corticosteroids on hemostasis in healthy subjects","volume":"14","author":"Majoor","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Waljee, A.K., Wiitala, W.L., Govani, S., Stidham, R., Saini, S., Hou, J., Feagins, L.A., Khan, N., Good, C.B., and Vijan, S. (2016). Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158017"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jvs.2006.10.034","article-title":"Risk factors and clinical impact of postoperative symptomatic venous thromboembolism","volume":"45","author":"Gangireddy","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","article-title":"Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis","volume":"12","author":"Sarlos","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/MIB.0000000000000310","article-title":"Prevention and treatment of venous thromboembolism in patients with IBD: A trail still climbing","volume":"21","author":"Papa","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/j.1572-0241.2001.04127.x","article-title":"Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease","volume":"96","author":"Papa","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e4239","DOI":"10.1097\/MD.0000000000004239","article-title":"Thalidomide for inflammatory bowel disease: Systematic review","volume":"95","author":"Bramuzzo","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1007\/s12032-012-0290-0","article-title":"Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma","volume":"29","author":"Robak","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis. A meta-analysis","volume":"97","author":"Shamseddeen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","article-title":"BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Davies","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","article-title":"Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease","volume":"13","author":"Higgins","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E1438","DOI":"10.1503\/cmaj.161485","article-title":"Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumor necrosis factor-\u03b1 inhibitors or nonbiologic agents: A cohort study","volume":"189","author":"Desai","year":"2017","journal-title":"CMAJ"},{"key":"ref_31","first-page":"269","article-title":"Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn\u2019s disease","volume":"27","author":"Hommes","year":"1997","journal-title":"Haemostasis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.4049\/jimmunol.176.4.2617","article-title":"TNF-alpha blockade down-regulates the CD40\/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn\u2019s disease","volume":"176","author":"Danese","year":"2006","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000000301","article-title":"Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: A prospective study","volume":"21","author":"Bollen","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izy384","article-title":"Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn\u2019s Disease: A Post Hoc Analysis of GEMINI 2 and 3","volume":"25","author":"Sands","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","first-page":"412","article-title":"Long-term Efficacy of Vedolizumab for Crohn\u2019s Disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_38","first-page":"400","article-title":"Long-term Efficacy of Vedolizumab for Ulcerative Colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cross, R.K., Chiorean, M., Vekeman, F., Xiao, Y., Wu, E., Chao, J., and Wang, A.W. (2019). Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225572"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn\u2019s Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn\u2019s Disease Who Failed Biologic Therapies: A National Cohort Study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xie, W., Xiao, S., Huang, Y., Sun, X., and Zhang, Z. (2019). Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Ther. Adv. Musculoskelet. Dis., 11.","DOI":"10.1177\/1759720X19895492"},{"key":"ref_46","unstructured":"US Food and Drug Administration (2019, October 17). Safety Trial Finds Risk of Blood Clots in the Lungs and Death with Higher dose of Tofacitinib (Xeljanz, Xeljanz XR) in Rheumatoid Arthritis Patients; FDA to Investigate, Available online: https:\/\/www.fda.gov\/media\/120485\/download."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/apt.15652","article-title":"Letter: Thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice","volume":"51","author":"Kotze","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sandborn, W.J., Ghosh, S., Panes, J., Schreiber, S., D\u2019Haens, G., Tanida, S., Siffledeen, J., Enejosa, J., Zhou, W., and Othman, A.A. (2020). Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis. Gastroenterology.","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: Efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"McKechnie, T., Wang, J., Springer, J.E., Gross, P.L., Forbes, S., and Eskicioglu, C. (2019). Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: A comprehensive systematic clinical review. Colorectal. Dis.","DOI":"10.1111\/codi.14853"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF03169142","article-title":"The incidence of postoperative venous thrombosis among patients with ulcerative colitis","volume":"174","author":"Cahill","year":"2005","journal-title":"Ir. J. Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ibd\/izz169","article-title":"Portomesenteric Venous Thrombosis in Patients Undergoing Surgery for Medically Refractory Ulcerative Colitis","volume":"26","author":"Kayal","year":"2020","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/DCR.0b013e3182698f60","article-title":"Venous thromboembolism after surgery for inflammatory bowel disease: Are there modifiable risk factors? Data from ACS NSQIP","volume":"55","author":"Wallaert","year":"2012","journal-title":"Dis. Colon Rectum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/DCR.0000000000001036","article-title":"Elevated Venous Thromboembolism Risk Following Colectomy for IBD Is Equal to Those for Colorectal Cancer for Ninety Days After Surgery","volume":"61","author":"Ali","year":"2018","journal-title":"Dis. Colon Rectum."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/DCR.0000000000000090","article-title":"The importance of extended postoperative venous thromboembolism prophylaxis in IBD: A National Surgical Quality Improvement Program analysis","volume":"57","author":"Gross","year":"2014","journal-title":"Dis. Colon Rectum."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1038\/ctg.2017.54","article-title":"Inflammatory Bowel Disease Adversely Impacts Colorectal Cancer Surgery Short-term Outcomes and Health-Care Resource Utilization","volume":"8","author":"Ramsey","year":"2017","journal-title":"Clin. Transl. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:47:29Z","timestamp":1760176049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072115"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072115","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]}}}